Drug Profile
Research programme: osteoporosis therapy - CollaGenex
Alternative Names: Osteoporosis therapy research programme - CollaGenexLatest Information Update: 04 Feb 2008
Price :
$50
*
At a glance
- Originator CollaGenex Pharmaceuticals
- Class
- Mechanism of Action Collagenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Osteoporosis
Most Recent Events
- 18 Mar 2003 No development reported - Preclinical for Osteoporosis in USA (unspecified route)
- 12 May 2000 CollaGenex Pharmaceuticals intends to pursue this research through partnership with another company
- 10 Feb 2000 Preclinical development for Osteoporosis in USA (Unknown route)